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Summary We have investigated the oestrogen receptor (ER) status of 20 cervical adenocarcinomas by
immunocytochemistry for ER protein and non-isotopic in situ hybridisation for ER mRNA. Both methods,
which are applicable to paraffin sections, were developed and validated in breast carcinomas with known ER
content. Six cervical adenocarcinomas contained immunocytochemically demonstrable ER protein; all con-
tained ER mRNA, but staining was less intense in poorly differentiated areas of four tumours. This disparity
between protein and mRNA detection needs further investigation as does the possibility that oestrogens may
play a role in the pathogenesis of cervical adenocarcinoma.
Adenocarcinoma of the cervix is a relatively rare tumour
which is increasing in incidence among young women (Peters
et al., 1986; Schwartz & Weiss, 1986; Chilvers et al., 1987).
Little is known of its aetiology and pathogenesis.
The cervix, like the breast, is a target tissue for oestrogens
and progesterone. This is shown by menstrual cycle related
alterations in the quality of cervical mucus (Wakefield &
Wells, 1985), and the demonstration of oestrogen and pro-
gesterone receptors in the normal cervix (Kupryjanczyk &
M6ller, 1988; Cano et al., 1990; Nonogaki et al., 1990).
While the clinical and biological significance of oestrogen
receptor status in breast carcinoma has been extensively
studied, very little factual information is available on the
presence of oestrogen receptors in cervical adenocarcinoma.
Having validated our methodology in a series of breast
carcinomas with known ER protein content, we studied ER
mRNA and protein content of 20 cervical adenocarcinomas.
Materials and methods
Immunocytochemistry
All tissues were fixed in 10% formol saline and embedded in
paraffin wax. Five ym sections were dewaxed, rehydrated and
immunostained using a modification of an avidin-
biotin-peroxidase complex technique for detection of ER
(Andersen et al., 1986; Cheng et al., 1988). After blocking
endogenous peroxidase activity the sections were digested at
37°C in a 0.02% Pronase E (Sigma, P6911) solution for
20-30min. The washed slides were incubated with normal
swine serum, followed by application of anti-ER monoclonal
antibody (H222) or control antibody (rat IgG) overnight at
room temperature. After washing, the slides were incubated
at room temperature with biotinylated sheep anti-rat IgG
(Amersham) for 30 min, and avidin-biotin complex (Dako)
for 1 h. The reaction was developed with diaminobenzidine.
The staining was intensified by immersing the slides for
10 min in 0.5% CuSO4 in 0.85% NaCl. Counterstaining was
performed with 1% methylgreen.
In situ hybridisation
A 24 base cDNA oligonucleotide probe (5' CTC CAG CTC
GTT CCC TTG GAT CTG 3') complementary to human
ER mRNA coding for amino acids 17-24 was synthesised to
our specifications (British Bio-technology Ltd., Abingdon,
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Oxon). This probe sequence is located within a 72 base
region of ER mRNA which shows no homology with
glucocorticoid, mineralocorticoid or progesterone receptors
(Green et al., 1986; Pelletier et al., 1988; Ponglikitmongkol et
al., 1988; Graham et al., 1991). The probe was labelled at the
5' end with digoxigenin-l 1-UTP and purified by HPLC. A 25
base oligoprobe complementary to human thyroglobulin
mRNA, also 5' labelled with digoxigenin-ll-UTP and syn-
thesised to our specifications (British Bio-technology Ltd.),
was used as an irrelevant control probe.
A standard in situ hybridisation method was used (Far-
quharson et al., 1990). All solutions were rendered RNAse
free by sterilisation and treatment with diethylpyrocarbonate.
The rehydrated sections were preincubated for 30 min in
0.2 M HCI and 15 mgml-' Proteinase K. After prehybridisa-
tion in hybridisation buffer containing 47% formamide for
1 h at 37°C, the sections were hybridised overnight at 42°C
with 1 ng ml-' ER oligoprobe. Control sections were
incubated in hybridisation buffer containing 0.75 ng ml-'
thyroglobulin probe. Additional control sections were
digested by RNAse A 1 mgml-' for 1 h at 37°C prior to
hybridisation, and others were hybridised in the absence of
labelled probe.
After hybridisation, sections were washed in graded con-
centrations of standard sodium citrate and incubated with an
alkaline phosphatase linked antidigoxigenin antibody (Boeh-
ringer Mannheim). The reaction was developed by overnight
incubation with 0.16 mg ml' bromochloro-indoylphosphate
and 0.33 mgml-' nitroblue tetrazolium.
Tumours studied
Nine breast carcinomas were selected to represent a range of
ER status as measured by enzyme immunosorbent assay
(EIA). This group included three breast carcinomas with no
detectable ER, three with high (>300 fmol mg cytosol
liquidised tissue) and three with intermediate (43-100
fmol mg-1) ER levels.
We used archival material from 20 adenocarcinomas of the
cervix from patients for whom follow-up was available. The
tumours were selected to represent various morphological
subtypes and grades of differentiation, and comprised 15
tumours of endocervical type, 3 clear cell carcinomas, 1
endometrioid carcinoma and 1 tumour of mixed endo-
cervical/intestinal differentiation.
Results
Positive staining for ER protein was denoted by brown
intranuclear staining while ER negative nuclei stained pale
green. ER mRNA was demonstrable as dark blue cytoplas-
mic staining. The sections were evaluated without prior
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knowledge of the biochemical status of these tumours and
the presence or absence of staining assessed subjectively. The
heterogeneity or otherwise of staining pattern was also noted.
Immunocytochemical staining was abolished when ER
antibody was replaced by control antibody. Cytoplasmic
mRNA staining was greatly diminished or abolished by pre-
incubation with RNAse. No staining was seen when the ER
probe was replaced by the control thyroglobulin probe or
when the test probe was omitted.
Breast carcinomas
All three breast carcinomas with a high ER status by EIA
showed strong positive staining for ER protein in the
majority of tumour nuclei and strong cytoplasmic staining
for ER mRNA (Figure 1). In those breast carcinomas with
an intermediate biochemical ER status, both immuno-
cytochemistry and in situ hybridisation showed more variable
results with a high proportion ofcells showing weak staining.
In the three tumours with biochemically undetectable ER,
immunocytochemistry showed large areas of negative stain-
ing with a few positive foci; the mRNA staining was indistin-
guishable from the intermediate group.
Cervical adenocarcinomas
Six of 20 cervical adenocarcinomas were ER positive on
immunocytochemistry (Figure 2); in five tumours ER protein
was demonstrated in the majority of epithelial nuclei
throughout the tumour, while one tumour showed focal
staining. There was no relationship between ER immuno-
reactivity and morphological subtype of tumour; all ER
positive tumours were well or moderately differentiated. Cer-
vical stromal fibroblasts and smooth muscle cells were con-
sistently strongly ER positive. Normal endocervical epithelial
cells showed variable ER positivity.
All the cervical adenocarcinomas were positive for ER
mRNA (Figure 3) while morphologically normal endocer-
vical epithelium was negative (Figure 4). Four cervical
adenocarcinomas showed an heterogeneous staining pattern
with reduction of mRNA staining in poorly differentiated
areas. Cervical stromal fibroblasts and smooth muscle cells
showed consistent cytoplasmic positivity.
Table I summarizes the age of the patients and clinical
outcome according to ER status. Fourteen patients survived
disease free for a mean of 51 months following presentation
(range 5-144), while five patients died of the disease (mean
11.6 months; range 2-28 months) and another died of treat-
ment complications. All six patients whose tumours con-
tained immunocytochemically demonstrable ER protein
remained disease free on follow-up for a mean of 43.5
months. Three of four patients with cervical adenocar-
cinomas showing a heterogeneous staining pattern for ER
mRNA died of the disease within a mean of 9 months (range
2-15) of presentation, the fourth was alive and disease free
at 14 months. In contrast, of 16 patients with tumours
showing diffuse ER mRNA staining, only two died of the
disease.
Discussion
Oestrogen receptor status has been found to be a useful
indicator of prognosis and response to endocrine manipula-
tion in breast carcinoma. Like the breast, the uterine cervix is
a target tissue for steroid hormones and contains oestrogen
receptors in endocervical epithelium, stromal cells and basal
layers of squamous epithelium (Kupryjanczyk & Moller,
1988; Cano et al., 1990; Nonogaki et al., 1990). In this
preliminary study we have shown, as far as we are aware for
the first time, that a proportion of cervical adenocarcinomas
also contain immunocytochemically detectable ER protein;
this finding was associated with a good prognosis. We have
further demonstrated that cervical adenocarcinomas contain
ER mRNA a heterogeneous staining pattern for which was
associated with a poor prognosis.
Previous studies using the dextran coated charcoal method
(Martin et al., 1978; Ford et al., 1983; Gao et al., 1983;
Figure 1 A breast carcinoma with high ER levels by enzyme immunosorbent assay showing: a, strong widespread
immunocytochemical staining for ER protein within nuclei of tumour cells. b, strong cytoplasmic staining for ER mRNA. x 200.1152 S.M. ISMAIL et al.
Figure 2 Adenocarcinoma of the cervix showing intranuclear localisation for ER protein. Cervical stromal fibroblasts and smooth
muscle showed consistent positive staining. x 200.
Figure 3 Same tumour as in Figure 2 showing cytoplasmic staining for ER mRNA. x 40.OESTROGEN RECEPTORS IN ADENOCARCINOMA OF CERVIX 1153
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Figure 4 Cervical adenocarcinoma showing cytoplasmic staining
for ER mRNA while the adjacent normal epithelium is negative.
x 180.
Martin et al., 1986; Potish et at., 1986; Hunter et at. 1987;
Harding et at., 1990) have reported a variable incidence of
ER positivity in cervical adenocarcinoma ranging from 23%/
to 81 %. These figures are difficult to interpret because of
variations among authors in the precise definition of receptor
positivity, the sampling problems inherent in biochemical
techniques which are only applicable to homogenised tissues
and the ER content of the normal cervix. The immuno-
cytochemical method we have used allows assessment of the
location of ER protein, whether in tumour or in normal
tissue, and has the additional advantage of being applicable
to archival material. In the only study which uses a com-
parable method (Nonogaki et at., 1990) none of the six
cervical adenocarcinomas examined showed ER immunoreac-
tivity.
All 20 tumours in our study showed cytoplasmic mRNA
staining while only six contained immunocytochemically
detectable ER protein. Thus there was an imbalance between
ER mRNA and protein detection in cervical adenocarcinomas.
Comparable findings have been reported for ER protein and
mRNA in breast carcinomas (Graham et al., 1991), and
calcitonin peptide and mRNA in medullary carcinomas of the
thyroid (Boultwood et al., 1990). In contrast to the cervical
adenocarcinomas, we found no demonstrable ER mRNA in
normal endocervical epithelium which nevertheless did contain
immunoreactive ER protein. Similarly, little or no calcitonin
mRNA staining was found in normal thyroid C cells which
contain abundant calcitonin peptide (Boultwood et al., 1990).
ThepaucityofmRNAinnormal tissuesmaybeexplained bythe
relativelylowturnover ofprotein orpeptideunderphysiological
conditions while therelative excess ofmRNA in neoplasms may
becaused by increased stability ofmRNA in tumours, increased
protein breakdown, or structural abnormalities in mRNA
which interfere with protein production. Existing evidence
provides examples of all these possibilities. For instance,
increased stability of c-myc mRNA has been observed in
Burkitt's lymphoma (Eick et al., 1985). In the human
papillomavirus (HPV) containing HeLa cervical carcinoma cell
line, increased protein breakdown is thought to account for the
absence of p53 protein in the presence of translatable p53
mRNA (Matlashewski et al., 1986; Scheffner et al., 1990).
Finally, several variant forms of ER mRNA and protein have
been described (Murphy, 1990; Fuqua etal., 1991) which do not
affect the region probed in our study,but which may lead to the
production of an abnormal ER protein which cannot be
detected by the standard antibody. The present study provides
no insight as to which of these possible mechanisms are
responsible for the disparity between ER mRNA and protein
detection in cervical adenocarcinoma.
The oestrogen receptor is a complex protein the physiology
and pathology ofwhich remain to be fully elucidated. However,
empirical detection of ER protein has provided an insight into
the pathogenesis ofbreast carcinoma and useful guidance in its
management. The findings of this preliminary study raise the
possibility that oestrogens may play acomparable pathogenetic
role in some cervical adenocarcinomas and that anti-oestrogen
therapy may be useful in a proportion of these tumours.
We thank Dr R.I. Nicholson for information regarding the biochemical
ER levels on our series ofbreast carcinomas and Dr J Gee for technical
advice with ER immunocytochemistry.
Table I Oestrogen receptor protein content, age and clinical outcome in the cervical
adenocarcinomas
Mean age Diseasefree Dead ofdisease
Number of (years)
ER status patients [range] Number Follow-upb Number SurvivaP
ICC positive 6 48.3 [29-83] 6 43.5 0 -
ICC negative 14a 51.7 [33-74] 8 56.6 5 11.6
mRNA diffuse 16a 48.9 [29-83] 13 53.8 2 20
mRNA heterogeneous 4 57.8 [49-74] 1 14 3 9
Total 20a 50.7 [29-83] 14 51 5 11.6
aThese figures include one patient who died of treatment complications and who therefore does not
appear in the survival data. bDuration in months.
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